

**Tafluprost Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

**Section 1: Identification**

Product name : Tafluprost Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908  
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800  
CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

**Section 2: Hazard identification****GHS Classification**

Not a hazardous substance or mixture.

**GHS label elements**

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

**Other hazards which do not result in classification**

None known.

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Glycerine	56-81-5	$\geq 1$ -< 10
Tafluprost	209860-87-7	$\geq 0.0003$ -< 0.0025

**Section 4: First-aid measures**

If inhaled : If inhaled, remove to fresh air.

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

In case of skin contact	: Get medical attention if symptoms occur. Wash with water and soap as a precaution.
In case of eye contact	: Get medical attention if symptoms occur. Flush eyes with water as a precaution.
If swallowed	: Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: None known.
Protection of first-aiders	: No special precautions are necessary for first aid responders.
Notes to physician	: Treat symptomatically and supportively.

**Section 5: Fire-fighting measures**

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

**Section 6: Accidental release measures**

Personal precautions, protective equipment and emergency procedures	: Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water.

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**Section 7: Handling and storage**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

**Section 8: Exposure controls/personal protection****Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Glycerine	56-81-5	WES-TWA (Mist)	10 mg/m3	NZ OEL

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

Tafluprost	209860-87-7	TWA	0.002 µg/m <sup>3</sup> (OEB 5)	Internal
Further information: Skin, Eye				
		Wipe limit	0.02 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** :

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

**Personal protective equipment**

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Organic vapour type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially

**Tafluprost Formulation**

Version 3.0	Revision Date: 03.12.2024	SDS Number: 558028-00017	Date of last issue: 28.09.2024 Date of first issue: 15.03.2016
----------------	------------------------------	-----------------------------	---

---

contaminated clothing.

---

**Section 9: Physical and chemical properties**

Appearance	:	Aqueous solution
Colour	:	clear
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics  
Particle size : No data available

**Section 10: Stability and reactivity**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

**Section 11: Toxicological information**

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Glycerine:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Guinea pig): > 5,000 mg/kg

**Tafluprost:**

Acute oral toxicity : LD50 (Rat): 665 mg/kg  
LD50 (Rat): > 100 mg/kg  
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : (Dog): 3 mg/kg  
Application Route: Intravenous  
Target Organs: Cardio-vascular system

**Skin corrosion/irritation**

Not classified based on available information.

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

---

**Components:****Glycerine:**

Species	: Rabbit
Result	: No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Glycerine:**

Species	: Rabbit
Result	: No eye irritation

**Tafluprost:**

Species	: Monkey
Result	: No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Tafluprost:**

Test Type	: Maximisation Test
Exposure routes	: Dermal
Species	: Guinea pig
Result	: Not a skin sensitizer.

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Glycerine:**

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test
	Result: negative
	Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: Chromosome aberration test in vitro
	Result: negative

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

**Tafluprost:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Glycerine:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

**Tafluprost:**

Species : Rat  
Application Route : Subcutaneous  
Exposure time : 24 Months  
Result : negative

Species : Mouse  
Application Route : Subcutaneous  
Exposure time : 18 Months  
Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Glycerine:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Tafluprost:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Intravenous injection  
Fertility: NOAEL: 100 µg/kg  
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 10 µg/kg  
Result: Malformations were observed., Reduced foetal weight

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 3 µg/kg

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 0.03 µg/kg  
Result: Malformations were observed.

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 0.01 µg/kg

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 1 µg/kg

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 0.3 µg/kg

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

---

**Components:****Tafluprost:**

Target Organs	: Lungs, Cardio-vascular system
Assessment	: Causes damage to organs.

**STOT - repeated exposure**

Not classified based on available information.

**Components:****Tafluprost:**

Target Organs	: Lungs, Cardio-vascular system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Glycerine:**

Species	: Rat
NOAEL	: 0.167 mg/l
LOAEL	: 0.622 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 13 Weeks

Species	: Rat
NOAEL	: 8,000 - 10,000 mg/kg
Application Route	: Ingestion
Exposure time	: 2 yr

Species	: Rabbit
NOAEL	: 5,040 mg/kg
Application Route	: Skin contact
Exposure time	: 45 Weeks

**Tafluprost:**

Species	: Rat
LOAEL	: 0.01 mg/kg
Application Route	: Intravenous
Exposure time	: 6 Months
Target Organs	: Cardio-vascular system, Blood, Bone marrow, Kidney, Liver, spleen

Species	: Dog
NOAEL	: 0.0001 mg/kg
LOAEL	: 0.001 mg/kg
Application Route	: Intravenous
Exposure time	: 39 Weeks
Target Organs	: Cardio-vascular system, Eye

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

---

|| Symptoms : Dilatation of the pupil

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Tafluprost:**

|| Eye contact : Symptoms: dryness of the eyes, Blurred vision

---

**Section 12: Ecological information****Ecotoxicity****Components:****Glycerine:**

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 1,955 mg/l Exposure time: 48 h
Toxicity to microorganisms	: NOEC (Pseudomonas putida): > 10,000 mg/l Exposure time: 16 h Method: DIN 38 412 Part 8

**Persistence and degradability****Components:****Glycerine:**

Biodegradability	: Result: Readily biodegradable. Biodegradation: 92 % Exposure time: 30 d Method: OECD Test Guideline 301D
------------------	---

**Bioaccumulative potential****Components:****Glycerine:**

Partition coefficient: n-octanol/water	: log Pow: -1.75
--	------------------

**Tafluprost:**

Partition coefficient: n-octanol/water	: log Pow: 4.5
--	----------------

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

**Mobility in soil**

No data available

**Other adverse effects**

No data available

**Section 13: Disposal considerations****Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**Section 14: Transport information****International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

**IATA-DGR**

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

**IMDG-Code**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

---

**National Regulations****NZS 5433**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Hazchem Code	:	Not applicable

**Special precautions for user**Not applicable

---

**Section 15: Regulatory information****Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

Not applicable

**Tolerable Exposure Limits (TEL)**

Not applicable

**Environmental Exposure Limits (EEL)**

Not applicable

**HSW Controls**

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**Section 16: Other information**

Revision Date : 03.12.2024

**Further information**

Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <a href="http://echa.europa.eu/">http://echa.europa.eu/</a>
---	---	---

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Tafluprost Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	03.12.2024	558028-00017	Date of first issue: 15.03.2016

---

Date format : dd.mm.yyyy

**Full text of other abbreviations**

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN